Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates and calculations
1.3.1 North America
1.3.2 Europe
1.3.3 Asia Pacific
1.3.4 Latin America
1.3.5 MEA
1.4 Forecast calculations
1.5 Data validation
1.6 COVID-19 impact analysis at global level
1.7 Data sources
1.7.1 Secondary
1.7.1.1 Paid sources
1.7.1.2 Unpaid sources
1.7.2 Primary
Chapter 2 Executive Summary
2.1 D-dimer testing market industry 3600synopsis, 2018 - 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Testing method trends
2.1.4 Application trends
2.1.5 End-use trends
Chapter 3 D-dimer Testing Industry Insights
3.1 Industry segmentation
3.2 Industry ecosystem analysis
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Growing prevalence of blood clotting related genetic disorders
3.3.1.2 Technological advancements regarding D-dimer testing
3.3.1.3 Increasing demand for next-generation point-of-care (POC) D-dimer tests
3.3.1.4 Government initiatives towards generating awareness regarding blood clotting disorders
3.3.2 Industry pitfalls & challenges
.3.3.2.1. Lack of trained healthcare professionals
3.3.2.2 Stringent reimbursement scenario
3.4 Growth potential analysis
3.4.1 By testing method
3.4.2 By application
3.4.3 By end-use
3.5 COVID- 19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive landscape
4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Competitive dashboard
4.4 Company market share, 2021
4.5 Competitive analysis of major market players
4.6 Competitive positioning matrix
4.7 Strategic outlook matrix
Chapter 5 D-dimer Testing Market and Forecast, By Testing Method (USD Million)
5.1 Key trends, by testing method
5.2 Enzyme-linked immunosorbent assay (ELISA)
5.3 Latex-enhanced immuno-turbidimetric assays
5.4 Fluorescence immunoassays
5.5 Others
Chapter 6 D-dimer Testing Market and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Deep vein thrombosis (DVT)
6.3 Pulmonary embolism (PE)
6.4 Disseminated intravascular coagulation (DIC)
6.5 Others
Chapter 7 D-dimer Testing Market and Forecast, By End-use (USD Million)
7.1 Key trends, by end-use
7.2 Hospitals
7.3 Diagnostic centers
7.4 Research institutes
7.5 Others
Chapter 8 D-dimer Testing Market and Forecast, By Region (USD Million)
8.1 Key regional trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Russia
8.3.7 Poland
8.3.8 Switzerland
8.3.9 Norway
8.3.10 Finland
8.3.11 Sweden
8.3.12 Denmark
8.3.13 The Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Vietnam
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Colombia
8.5.5 Chile
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Israel
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 BioMedica Diagnostics
9.3 biomérieux SA
9.4 Diazyme Laboratories Inc. (General Atomics)
9.5 F. Hoffmann-La Roche Ltd.
9.6 HORIBA Ltd.
9.7 Quidel Corporation
9.8 Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.)
9.9 Siemens Healthcare GmbH
9.10 Thermo Fisher Scientific Inc.
9.11 Unbound Medicine Inc
9.12 Werfen
